Access Program for Advanced Cholangiocarcinoma Treatment with ABC294640 (Yeliva ®)
Sponsor: RedHill Biopharma Limited
ClinicalTrials ID:NCT03414489
This program offers access to the investigational drug ABC294640 (Yeliva ®) for patients with advanced cholangiocarcinoma who cannot join the ongoing clinical trial. It is designed to provide treatment options before the drug is officially approved.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This expanded access program is for patients with advanced cholangiocarcinoma (a type of bile duct cancer) who cannot participate in the current clinical trial for ABC294640 (Yeliva ®) or cannot reach the trial locations. The program allows these patients to receive the drug before it is approved by health authorities. Availability depends on where you live, and new sites will be added as they are approved. An oncologist will determine if the potential benefits of the drug outweigh the risks based on your medical history and eligibility.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with cholangiocarcinoma (bile duct cancer).
- Cannot join the ABC294640 clinical trial due to ineligibility or location issues.
- Considered suitable for treatment with ABC294640 by your oncologist.
- Willing to sign a consent form agreeing to the treatment.
- Your oncologist must have approval from RedHill to provide the drug.
- The program must be approved by local health authorities.
Exclusion Criteria
- Any medical condition that could make treatment with ABC294640 unsafe, as determined by RedHill.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.